Tigecycline activity against geographically diverse Enterobacteriaceae displaying multidrug-resistant phenotypes across Europe
Abstract number: P1173
Pillar C., Draghi D., Thornsberry C., Sahm D., Dowzicky M.
Objective: Infections derived from Enterobacteriaceae (EN) commonly occur among hospitalised patients and can be problematic to treat. Tigecycline, a new semi-synthetic derivative of minocycline and the first in the glycylcycline class of antibiotics, has previously shown activity against this family of organisms (Org). In 2006, tigecycline (TIG) was approved in Europe (EU) for treatment of complicated skin and skin structure infections and complicated intra-abdominal infections.
Methods: In total, 875 EN isolates were obtained from 28 hospitals in ten countries across EU during 2006 to 2007. Isolates were tested centrally by broth microdilution (CLSI M7-A7). TIG activity was analysed by MDR status defined as resistance to 3 agents which included ampicillin, cefepime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, minocycline, and piperacillin-tazobactam. EUCAST breakpoints were used to interpret TIG MIC results and CLSI (M100-S17) breakpoints were used to interpret all other agents, where applicable.
Results: See Table.
Conclusions: Overall, EN was 97% susceptible to TIG. The TIG MIC90 against all EN tested did not exceed 2 mg/L, regardless of MDR phenotype. The potential for resistance to any new agent to increase with use and time dictates the need for continuous monitoring of TIG activity against this group of target pathogens.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|